Search

Displaying results 641 - 650 of 4207 in total
  1. Drug

    Zopapogene imadenovec

    go.drugbank.com/drugs/DB24672
    ApprovedInvestigational

    Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory … [L54071] It is the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081]

  2. Drug

    Baclofen

    go.drugbank.com/drugs/DB00181
    ApprovedInvestigational

    Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.

  3. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_. … Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016.[L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018.

  4. Drug

    Ceftazidime

    go.drugbank.com/drugs/DB00438
    ApprovedInvestigational

    [L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of

  5. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    [erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors … [A263973] It is used to treat anemia in patients with myelodysplastic syndromes (MDS), a group of hematologic disorders characterized by ineffective hematopoiesis, peripheral cytopenia, abnormal marrow

  6. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.

  7. Drug

    Sennosides

    go.drugbank.com/drugs/DB11365
    ApprovedInvestigational

    The medication is taken by mouth or via the rectum[FDA Label]. It typically begins working in minutes when given by rectum and within twelve hours when given by mouth[FDA Label].

  8. Drug

    Omeprazole

    go.drugbank.com/drugs/DB00338
    ApprovedInvestigationalVet approved

    Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. … These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid.

  9. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. … [L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for

  10. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    by the U.S. … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved